Location History:
- Singapore, SG (2010)
- Dallas, TX (US) (2011)
Company Filing History:
2 out of 3,540 
2 out of 5,463 
Years Active: 2010-2011
Title: A John Rush: Innovator in Antidepressant Treatment
Introduction
A John Rush is a notable inventor based in Dallas, TX (US), recognized for his contributions to the field of mental health treatment. He holds 2 patents that focus on methods to improve patient outcomes during antidepressant therapy. His innovative approaches aim to identify patients at risk of adverse events and predict treatment responses.
Latest Patents
One of Rush's latest patents is titled "Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication." This invention provides a method for screening patients to identify those more likely to exhibit an increased risk of treatment-emergent suicidal ideation. The process involves obtaining a sample of genetic material from patients and assaying it for the presence of specific genotypes associated with increased risk. The genotypes are characterized by polymorphisms in genes such as glutamine receptor, ionotropic, kainate 2 (GRIK2) and glutamate receptor ionotropic AMPA 3 (GRIA3).
Another significant patent is "Methods to predict the outcome of treatment with antidepressant medication." This invention outlines a method for determining the outcome of treatment in patients. It focuses on screening patients to identify those with a decreased risk of non-response to antidepressant medication by analyzing genetic material for specific genotypes. The relevant genotypes are characterized by polymorphisms in the genes HTR2A, GRIK4, and BCL2.
Career Highlights
Throughout his career, A John Rush has worked with prominent organizations, including the United States Department of Health and Human Services and the University of Texas System. His work has significantly impacted the understanding and treatment of mental health conditions.
Collaborations
Rush has collaborated with esteemed colleagues such as Francis J McMahon and Gonzalo E Laje, contributing to advancements in the field of psychiatry and patient care.
Conclusion
A John Rush's innovative patents and collaborations highlight his commitment to improving mental health treatment. His work continues to influence the way antidepressant therapies are approached, ultimately benefiting patients at risk of adverse effects.